Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform
Retrieved on:
Tuesday, October 4, 2022
Biotechnology, Professional Services, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Science, Clinical Trials, Finance, Entrepreneurship, Doctor of Philosophy, Physics, Sibylla, Technology, Biotechnology, National Institute, Protein folding, Intermediate, Protein, University of Trento, University of Perugia, Trento, Cyclin D1, Cancer, Nikos Vertis, University, FIDS, Therapy, Fine chemical
We have gained the support of a strong group of expert investors and the capital to advance our small molecule pipeline, expand our protein folding simulation technology platform and bring additional expertise to our team.
Key Points:
- We have gained the support of a strong group of expert investors and the capital to advance our small molecule pipeline, expand our protein folding simulation technology platform and bring additional expertise to our team.
- Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein.
- Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state.
- Vertis SGR funded the breakthrough discovery technology resulting from the collaboration, enabling the initial validation of Sibyllas technology.